Prof. Dr. Andreas Pahl

Management Board

DE·BaFin

Heidelberg Pharma AG

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

—

Latest filing published 25 Jul 2025 for Heidelberg Pharma AG, €170k. Read the official filing

Insider track record

Disclosed buys

Disclosed sells

Signal history

No signal scores available.

Prof. Dr. Andreas Pahl: trading record in brief

Prof. Dr. Andreas Pahl (senior executive) discloses dealings in Heidelberg Pharma AG to BaFin. In total, 2 filings cover trades dated 23 July 2025.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

Most recently, on 25 July 2025, the filings show a transaction worth €170k in Heidelberg Pharma AG. These figures are compiled from regulatory filings published by BaFin. They describe what insiders did and are not a recommendation.